The 56 Point TA; Charts With an Attitude Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug R who wrote (55882)	1/1/2020 5:13:26 PM
From: FJV	Read Replies (1) of 79477

Earlier this week the FDA approved the Merck/Astrazeneca's PARP inhibitor LYNPARZA and it is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer. Biomarker-selected patients is what ONCY's predictive biomarker is doing to identify patients who will postively respond to combination therapy in multiple cancers including breast and metastatic pancreatic cancer. This week, the market connected the dots. It looks like ONCY may become a monster in 2020.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next